EPHA2 and neoplasm: PLCγ1 promotes tumor cell proliferation in KRAS-mutant LC cells, suggesting that PLCγ1 is a novel interactor of the EphA2 RTK in LC cells and that the EphA2–PLCγ1 signaling axis could be a promising therapeutic strategy for treating LC [68].